Endocrine Abstracts

Aim: We compared effectiveness of partial withdrawal of levothyroxine (L-T4) to the use of recombinant human TSH (rhTSH) in preparation for Tg testing. We also evaluated clinical aspects and quality-of-life (QOL) during both regimens.Materials and methods: Ten consecutive patients, previously treated with total thyroidectomy and radioiodine ablation for DTC, underwent rhTSH protocol and, after 15 days, reduced their L-T4 dose by 50% for 5 weeks. At the f...

Radioiodide 131I (RAI) is the therapy of choice for radioiodine-avid differentiated thyroid cancer (DTC). However, 5–15% of DTC patients become RAI refractory (RAIR), and the 10-year survival rate for metastatic disease decreases to 10%. The failure of RAI response is mainly due to the loss of thyroid differentiation, that leads to the loss of expression/function of components of iodide metabolism, first of all the Na/I symporter (NIS). The finding that the MAPK pathway i...

Although differentiated thyroid cancer (DTC) has the third highest propensity to spread to the bone after breast and prostate cancer, there is a paucity of data concerning the treatment of bone metastasis (BM) in this setting. The MOSCATI (Metastasi OSsee da Carcinoma TIroideo) was a multicenter, retrospective study investigating the real-life outcome and management of BM in 143 patients (80 F, 63 M; median age 60 years) with DTC involving 10 specialized cente...